Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

SSIGN Score (Mayo)

The SSIGN (Stage, Size, Grade, and Necrosis) score from the Mayo Clinic predicts cancer-specific survival in patients with clear cell renal cell carcinoma (ccRCC).

Evidence-based context for fast calculator use

Purpose:
SSIGN Score predicts cancer-specific survival in clear cell renal cell carcinoma using pathologic stage, tumor size, nuclear grade, and necrosis.
Population:
patients undergoing localized or metastatic renal cell carcinoma prognostic assessment
Factors:
Pathologic T-Stage, Nodal Status, Metastasis, Tumor Size, Fuhrman Nuclear Grade, Tumor Necrosis
Reference:
Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-2400.
HomeSSIGN Score (Mayo)
Pin your most used calculators here by clicking the star in the dropdown.

SSIGN Score (Mayo)

Clinical Context & Background

The SSIGN (Stage, Size, Grade, and Necrosis) score from the Mayo Clinic predicts cancer-specific survival in patients with clear cell renal cell carcinoma (ccRCC). It is commonly used for both localized and metastatic patients to estimate long-term outcomes.
Primary Source EvidenceFrank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-2400.
Formula Logic
Sum of points derived from Stage, Size, Grade, and Necrosis.

Reference Data

SSIGN Score5-Year Cancer Specific Survival
0 - 297 - 99%
3 - 489 - 95%
5 - 677 - 85%
7 - 942 - 62%
≥ 1018 - 25%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use SSIGN Score (Mayo) when sSIGN Score predicts cancer-specific survival in clear cell renal cell carcinoma using pathologic stage, tumor size, nuclear grade, and necrosis.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 2 through ≥ 10.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, localized versus metastatic setting, nephrectomy status, treatment line, and imaging before selecting surveillance or systemic-therapy pathways.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Post-nephrectomy and metastatic RCC models are not interchangeable.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing localized or metastatic renal cell carcinoma prognostic assessment

How to apply this result

For a representative case, verify Pathologic T-Stage, Nodal Status, Metastasis, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Kidney / Renal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell CarcinomaMSKCC (Motzer) ScoreLeibovich Score (RCC)

Frequently Asked Questions

When should SSIGN Score (Mayo) be used?

Use it for patients undergoing localized or metastatic renal cell carcinoma prognostic assessment when all required inputs and the intended clinical setting are confirmed.

Can SSIGN Score (Mayo) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.